Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag

Volume: 10 Number: 1 April 1, 2017
  • Sinem Namdaroğlu
  • Şerife Solmaz Medeni
  • Tuğba Çetintepe
  • Ozan Barış Namdaroğlu
  • Oktay Bilgir
EN TR

Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag

Abstract

Antiphospholipid antibody syndrome (APS) is a systemic autoimmune disorder characterized by recurrent arterial or venous thrombosis, fetal loss, thrombocytopenia, neurological symptoms and presence of serum antiphospholipid antibodies (AFA). In this report,we present a young male patient with thrombocytopenia who was refractory to steroids, intravenous immunoglobulin and splenectomy but had complete response to eltrombopag treatment, FV Leiden heterozygous mutant positive, also had a history of sinüs thrombosis taking oral anticoagulant treatment has been diagnosed primary APS. Eltrombopag treatment primary antiphospholipid syndrome patient associated with refractory thrombocytopenia.

Keywords

Details

Primary Language

English

Subjects

-

Journal Section

-

Authors

Sinem Namdaroğlu This is me

Şerife Solmaz Medeni This is me

Tuğba Çetintepe This is me

Ozan Barış Namdaroğlu This is me

Oktay Bilgir This is me

Publication Date

April 1, 2017

Submission Date

April 1, 2017

Acceptance Date

-

Published in Issue

Year 2017 Volume: 10 Number: 1

APA
Namdaroğlu, S., Medeni, Ş. S., Çetintepe, T., Namdaroğlu, O. B., & Bilgir, O. (2017). Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag. Pamukkale Medical Journal, 10(1), 67-72. https://izlik.org/JA77UN57PT
AMA
1.Namdaroğlu S, Medeni ŞS, Çetintepe T, Namdaroğlu OB, Bilgir O. Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag. Pam Med J. 2017;10(1):67-72. https://izlik.org/JA77UN57PT
Chicago
Namdaroğlu, Sinem, Şerife Solmaz Medeni, Tuğba Çetintepe, Ozan Barış Namdaroğlu, and Oktay Bilgir. 2017. “Primary Antiphospholipid Syndrome Patient Associated With Refractory Thrombocytopenia and Factor V Leiden Mutation Treated With Eltrombopag”. Pamukkale Medical Journal 10 (1): 67-72. https://izlik.org/JA77UN57PT.
EndNote
Namdaroğlu S, Medeni ŞS, Çetintepe T, Namdaroğlu OB, Bilgir O (April 1, 2017) Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag. Pamukkale Medical Journal 10 1 67–72.
IEEE
[1]S. Namdaroğlu, Ş. S. Medeni, T. Çetintepe, O. B. Namdaroğlu, and O. Bilgir, “Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag”, Pam Med J, vol. 10, no. 1, pp. 67–72, Apr. 2017, [Online]. Available: https://izlik.org/JA77UN57PT
ISNAD
Namdaroğlu, Sinem - Medeni, Şerife Solmaz - Çetintepe, Tuğba - Namdaroğlu, Ozan Barış - Bilgir, Oktay. “Primary Antiphospholipid Syndrome Patient Associated With Refractory Thrombocytopenia and Factor V Leiden Mutation Treated With Eltrombopag”. Pamukkale Medical Journal 10/1 (April 1, 2017): 67-72. https://izlik.org/JA77UN57PT.
JAMA
1.Namdaroğlu S, Medeni ŞS, Çetintepe T, Namdaroğlu OB, Bilgir O. Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag. Pam Med J. 2017;10:67–72.
MLA
Namdaroğlu, Sinem, et al. “Primary Antiphospholipid Syndrome Patient Associated With Refractory Thrombocytopenia and Factor V Leiden Mutation Treated With Eltrombopag”. Pamukkale Medical Journal, vol. 10, no. 1, Apr. 2017, pp. 67-72, https://izlik.org/JA77UN57PT.
Vancouver
1.Sinem Namdaroğlu, Şerife Solmaz Medeni, Tuğba Çetintepe, Ozan Barış Namdaroğlu, Oktay Bilgir. Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag. Pam Med J [Internet]. 2017 Apr. 1;10(1):67-72. Available from: https://izlik.org/JA77UN57PT

Creative Commons Lisansı
Pamukkale Medical Journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License